Long-Term Safety Extension With SR57667B in Patients With Alzheimer's Disease
Status:
Completed
Trial end date:
2006-11-01
Target enrollment:
Participant gender:
Summary
The primary objective is to assess the long term safety/tolerability of 4 mg/day of SR57667B
in comparison to placebo in patients with mild-to-moderate Alzheimer's Disease (AD).
A secondary objective is to describe the long term progression of Alzheimer's symptoms in
patients treated by 4 mg/day of SR57667B.